Skip to content

Study · Animal study (in vivo) · rat · 2002

1 result

[Neuroprotective effects of semax in MPTP-induced disturbances of brain dopamine system].

Levitskaia NG, Sebentsova EA, Andreeva LA, Alfeeva LIu, Kamenskiĭ AA, Miasoedov NF

Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova1 Nov 2002Cited by 1 (Europe PMC)

PMID12587264 (opens in a new tab)PepBankPUB-12587264
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with MPTP-induced dopamine system disturbance, intranasal semax attenuated the neurotoxin-induced behavioural disturbances.

    In plain wordsIn rats given a brain toxin, semax through the nose reduced the behaviour problems that the toxin caused.

    Peptide
    Semax
    Outcome
    DecreaseBehavioural disturbances after MPTP
    Study

    ratsn: not reported in source

    MPTP-induced disturbance of brain dopamine system
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    0.2 mg/kg daily · intranasalAs given in this study (rats).

    Source sentences

    Summary
    Semax administration (daily intranasal 0.2 mg/kg) attenuated behaviour disturbances induced by neurotoxin.
    2 context sentences
    Summary · context
    It was shown that MPTP administration (25 mg/kg) reduced motor activity and auhmented the anxiety level in rats.
    Summary · context
    Effects of an ACTH (4-10) analogue Semax (MEHFPGP) on behaviour of white rats with MPTP-induced disturbances of brain DA-system have been studied.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.